Business Development

Our success lies in our unique ability to identify novel targets across different therapeutic areas and our talent in progressing compounds with novel modes of action quickly through preclinical development up to clinical proof of concept.

OncoArendi is interested in establishing new alliances and partnerships early in the drug development process to leverage its core competencies: identifying novel targets, expanding understanding of the biology of diseases and developing therapeutics with novel modes of action that impact patient care. OncoArendi is planning to advance its programs up to Phase II clinical trials, and intends to out-license or otherwise partner late preclinical and clinical phase drug candidates.


meatnetadmBusiness Development